Soley Therapeutics

United States - South San Francisco, California

• 09/01/2026
• Series C
• $200,000,000

Soley Therapeutics is a science-first, tech-enabled drug discovery and development company using cells as the world’s most powerful sensors to uncover first-in-class medicines. Soley’s platform translates the cellular information of stress biology into mechanistic insight, revealing novel drug candidates that otherwise would be missed. Soley deploys full-stack AI via its collaboration with Oracle, including OCI AI Infrastructure, NVIDIA AI Enterprise and NVIDIA Blackwell GPUs. By combining foundational biology, proprietary imaging, first-in-class automation, and integrated AI tools, Soley has rapidly built a pipeline that spans oncology, neurodegenerative disorders, metabolic diseases, and other areas. Soley is headquartered in South San Francisco.

Related People

Yerem YeghiazariansFounder

United States - San Francisco, California

Professor of Medicine
Past Leone-Perkins Family Endowed Chair in Cardiology
San Francisco Board Past-President, American Heart Association
Past Co-Director, Adult Cardiac Catheterization Laboratory
Past Director, Peripheral Interventional Cardiology Program
Past Director, Translational Cardiac Stem Cell Program
Cardiovascular Research Institute
Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research
Associate Member in Experimental Therapeutics, UCSF Helen Diller Cancer Center
University of California, San Francisco

LinkedIn https://www.linkedin.com/in/yerem-yeghiazarians-4b561b1a/